lifestyle.celebhomes.net
Home
Sample Page
Author:
NEUROCRINE BIOSCIENCES, INC.
Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio
April 6, 2026
Neurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings
March 26, 2026
Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer
March 17, 2026
Neurocrine Biosciences to Present at the Stifel 2026 Virtual CNS Forum
March 10, 2026
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia
January 27, 2026
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial Results
January 23, 2026
Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 5, 2026
Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy
December 22, 2025
Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology
December 18, 2025
Neurocrine Biosciences to Host R&D Day on December 16
December 10, 2025
←
Previous Page
1
2
3
Next Page
→